| Integrated molecular analysis of adult T cell leukemia/lymphoma K Kataoka, Y Nagata, A Kitanaka, Y Shiraishi, T Shimamura, J Yasunaga, ... Nature genetics 47 (11), 1304-1315, 2015 | 805 | 2015 |
| Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers K Kataoka, Y Shiraishi, Y Takeda, S Sakata, M Matsumoto, S Nagano, ... Nature 534 (7607), 402-406, 2016 | 651 | 2016 |
| Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F K Shide, HK Shimoda, T Kumano, K Karube, T Kameda, K Takenaka, ... Leukemia 22 (1), 87-95, 2008 | 228 | 2008 |
| Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma K Kataoka, M Iwanaga, J Yasunaga, Y Nagata, A Kitanaka, T Kameda, ... Blood, The Journal of the American Society of Hematology 131 (2), 215-225, 2018 | 135 | 2018 |
| TET2 is essential for survival and hematopoietic stem cell homeostasis K Shide, T Kameda, H Shimoda, T Yamaji, H Abe, A Kamiunten, M Sekine, ... Leukemia 26 (10), 2216-2223, 2012 | 109 | 2012 |
| Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator T Kameda, K Shide, T Yamaji, A Kamiunten, M Sekine, Y Taniguchi, ... Blood, The Journal of the American Society of Hematology 125 (2), 304-315, 2015 | 95 | 2015 |
| Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib K Shide, T Kameda, T Yamaji, M Sekine, N Inada, A Kamiunten, K Akizuki, ... Leukemia 31 (5), 1136-1144, 2017 | 78 | 2017 |
| JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation S Oku, K Takenaka, T Kuriyama, K Shide, T Kumano, Y Kikushige, ... British journal of haematology 150 (3), 334-344, 2010 | 71 | 2010 |
| Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis H Kakumitsu, K Kamezaki, K Shimoda, K Karube, T Haro, A Numata, ... Leukemia research 29 (7), 761-769, 2005 | 69 | 2005 |
| Signal transducers and activators of transcription 3 augments the transcriptional activity of CCAAT/enhancer-binding protein α in granulocyte colony-stimulating factor … A Numata, K Shimoda, K Kamezaki, T Haro, H Kakumitsu, K Shide, K Kato, ... Journal of Biological Chemistry 280 (13), 12621-12629, 2005 | 69 | 2005 |
| Whole-genome landscape of adult T-cell leukemia/lymphoma Y Kogure, T Kameda, J Koya, M Yoshimitsu, K Nosaka, J Yasunaga, ... Blood, The Journal of the American Society of Hematology 139 (7), 967-982, 2022 | 54 | 2022 |
| Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms Y Nakaya, K Shide, T Niwa, J Homan, S Sugahara, T Horio, K Kuramoto, ... Blood cancer journal 1 (7), e29-e29, 2011 | 50 | 2011 |
| The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan K Shimoda, K Shide, K Kamezaki, T Okamura, N Harada, N Kinukawa, ... International journal of hematology 85, 338-343, 2007 | 50 | 2007 |
| The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan T Hidaka, K Shide, H Shimoda, T Kameda, K Toyama, K Katayose, ... European journal of haematology 83 (4), 328-333, 2009 | 38 | 2009 |
| Elevated HIF-1α expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy T Matsunaga, O Imataki, E Torii, T Kameda, K Shide, H Shimoda, ... Leukemia research 36 (6), e122-e124, 2012 | 37 | 2012 |
| Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils Y Kimishima, T Misaka, T Yokokawa, K Wada, K Ueda, K Sugimoto, ... Nature Communications 12 (1), 6177, 2021 | 33 | 2021 |
| Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice Y Ozono, K Shide, T Kameda, A Kamiunten, Y Tahira, M Sekine, K Akizuki, ... Leukemia 35 (2), 454-467, 2021 | 32 | 2021 |
| Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis Y Nakaya, K Shide, H Naito, T Niwa, T Horio, J Miyake, K Shimoda Blood cancer journal 4 (1), e174-e174, 2014 | 32 | 2014 |
| R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm K Shide, T Kameda, V Markovtsov, HK Shimoda, E Tonkin, S Fang, C Liu, ... Blood, The Journal of the American Society of Hematology 117 (25), 6866-6875, 2011 | 29 | 2011 |
| p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation A Furuhata, A Kimura, K Shide, K Shimoda, M Murakami, H Ito, S Gao, ... Biochemical and biophysical research communications 383 (4), 411-416, 2009 | 27 | 2009 |
